256 related articles for article (PubMed ID: 32899879)
21. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
22. Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):785-790. PubMed ID: 32768385
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of Transcript-Type
Molica M; Abruzzese E; Breccia M
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
[TBL] [Abstract][Full Text] [Related]
24. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
25. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
27. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.
Iurlo A; Cattaneo D; Artuso S; Consonni D; Abruzzese E; Binotto G; Bocchia M; Bonifacio M; Castagnetti F; Galimberti S; Gozzini A; Iezza M; Latagliata R; Luciano L; Maggi A; Miggiano MC; Pregno P; Rege-Cambrin G; Russo S; Scortechini AR; Tafuri A; Tiribelli M; Fava C; Rosti G; Foa R; Breccia M; Saglio G
Front Oncol; 2022; 12():839915. PubMed ID: 35311109
[TBL] [Abstract][Full Text] [Related]
28. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
29. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.
Millot F; Suttorp M; Ragot S; Leverger G; Dalle JH; Thomas C; Cheikh N; Nelken B; Poirée M; Plat G; Versluys B; Lausen B; Borisevich M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439257
[TBL] [Abstract][Full Text] [Related]
30. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
31. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Saifullah HH; Lucas CM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439327
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
33. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.
Chen K; Ruan Y; Tian K; Xiong P; Xia N; Li J; Huang W; Cao F; Chen Q
Front Oncol; 2022; 12():841546. PubMed ID: 35223524
[TBL] [Abstract][Full Text] [Related]
34. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F; Kim A; Khoury JH; Kota VK
J Clin Med; 2020 May; 9(5):. PubMed ID: 32443762
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract][Full Text] [Related]
37. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Marcé S; Xicoy B; García O; Cabezón M; Estrada N; Vélez P; Boqué C; Sagüés M; Angona A; Teruel-Montoya R; Ferrer-Marín F; Amat P; Hernández-Boluda JC; Ibarra MM; Anguita E; Cortés M; Fernández-Ruiz A; Fontanals S; Zamora L; On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300312
[TBL] [Abstract][Full Text] [Related]
38. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.
Chen KK; Du TF; Xiong PS; Fan GH; Yang W
Front Oncol; 2019; 9():372. PubMed ID: 31139566
[No Abstract] [Full Text] [Related]
40. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Pavlovsky C; Abello Polo V; Pagnano K; Varela AI; Agudelo C; Bianchini M; Boquimpani C; Centrone R; Conchon M; Delgado N; Funke V; Giere I; Luise I; Meillon L; Moiraghi B; Navarro JR; Pilleux L; Prado AI; Undurraga S; Cortes J
Blood Adv; 2021 Dec; 5(23):4855-4863. PubMed ID: 34438444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
